Top Industry Leaders in the Lichen Nitidus Treatment Market
Pfizer Launches Initiative for Personalized Dermatology Treatments: Pfizer has announced a new initiative focused on developing personalized treatments for various skin conditions, including eczema, psoriasis, and inflammatory skin diseases. This initiative could potentially lead to advancements in understanding the underlying causes of skin conditions and developing individualized treatment plans for patients with Lichen Nitidus in the future.
FDA Approves First Biosimilar for Dupixent: The FDA recently approved the first biosimilar version of Dupixent (dupilumab), a medication used to treat moderate to severe eczema. This could increase access to this effective treatment for a wider range of patients, potentially benefiting individuals with Lichen Nitidus who might also respond well to dupilumab.
List of Lichen Nitidus Treatment Key Companies in the Market
- Pfizer Inc. (U.S)
- Novartis AG (Switzerland)
- Merck Sharp & Dohme Corp.
- a subsidiary of Merck & Co.Inc. (U.S)
- Sanofi (France)
- GlaxoSmithKline plc. (U.K)
- AstraZeneca (U.K)
- Hubei Gedian Humanwell Pharmaceutical Co.,Ltd (China)
- Farmabios SPA (Italy)
- Horizon Pharma plc. (Ireland)
